Scarica l'app Stockscreener
0.391
3.34%
-0.0135
Pre-mercato:
.39
-0.001
-0.26%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Leap Therapeutics Inc Borsa (LPTX) Ultime notizie
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline - Investing.com India
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com
Sun Pharma's Strategic Leap: Acquiring Checkpoint Therapeutics - Devdiscourse
Checkpoint Therapeutics Shares Leap Premarket on Takeover by Sun Pharma -March 10, 2025 at 06:24 am EDT - Marketscreener.com
Leap Therapeutics (LPTX) to Release Quarterly Earnings on Monday - Defense World
Gastric Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Earnings To Watch: L.B. Foster (FSTR) Reports Q4 Results Tomorrow - The Globe and Mail
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors - ACCESS Newswire
Nebius Stock Investors Have Reason to Cheer as the Company Expands Rapidly Into AI Infrastructure - The Globe and Mail
Leap Therapeutics stock hits 52-week low at $0.47 amid downturn - Investing.com Canada
Keurig Dr Pepper Earnings: What To Look For From KDP - The Globe and Mail
Amicus Therapeutics’ Bold Leap Toward Billion-Dollar Milestone - Smartphone Magazine
Cathie Wood Keeps Dumping Palantir Stock. Should You? - The Globe and Mail
Got $3,500? Should You Buy Ethereum or XRP (Ripple)? - The Globe and Mail
Biliary Tumor Market Set to Grow Substantially Through 2032, - openPR
Recent Insider Activity Suggests Potential Gains for Vaxart Inc (VXRT) - Knox Daily
Analytical Lens: Exploring Leap Therapeutics Inc (LPTX)’s Financial Story Through Ratios - The Dwinnex
Biliary Tract Cancer Pipeline 2024: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Agios Pharma, Servier Pharma, Merck Sharp & Dohme, AstraZeneca, Taiho Onco - Barchart
Get in on Leap Therapeutics Inc’s (LPTX) buy-in window today! - SETE News
Leap Therapeutics Inc (LPTX) stock analysis: A simple moving average approach - US Post News
China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment - Yahoo Finance
What is HC Wainwright's Estimate for LPTX FY2029 Earnings? - MarketBeat
Analyzing Leap Therapeutics Inc (NASDAQ: LPTX) Stock’s Performance and Trends for Investment - Marketing Sentinel
Leap Therapeutics (NASDAQ:LPTX) Downgraded by Baird R W to "Hold" - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
Leap Therapeutics (NASDAQ:LPTX) Cut to "Neutral" at Robert W. Baird - MarketBeat
FY2029 Earnings Estimate for LPTX Issued By HC Wainwright - Defense World
Robert W. Baird Downgrades Leap Therapeutics (NASDAQ:LPTX) to Neutral - Defense World
Leap Therapeutics (NASDAQ:LPTX) Rating Lowered to “Neutral” at HC Wainwright - Defense World
Needham & Company LLC Upgrades Open Lending (NASDAQ:LPRO) to Buy - Defense World
Leap Therapeutics Reports Promising Initial Clinical Data, Updates Corporate Presentation - Defense World
Baird R W Downgrades Leap Therapeutics (NASDAQ:LPTX) to Hold - Defense World
Leap reports positive colorectal cancer study results - MSN
Leap Therapeutics stock rating cut by H.C. Wainwright to Neutral - MSN
Baird cuts Leap Therapeutics stock rating, slashes target - MSN
Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer - Nature.com
Leap Therapeutics stock hits 52-week low at $0.8 - MSN
Leap Therapeutics cut to Neutral at Baird after mid-stage trial setback - MSN
Leap Therapeutics Shares Tumble After Downgrades from Baird, HC Wainwright -January 29, 2025 at 03:02 pm EST - Marketscreener.com
Leap Therapeutics stock cut to Neutral at Baird (LPTX:NASDAQ) - Seeking Alpha
This Apple Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Biliary Tract Cancer Market Poised for Significant Growth from - openPR
Baird Downgrades Leap Therapeutics to Neutral From Outperform, Cuts Price Target to $1.25 From $9 - Marketscreener.com
HC Wainwright Downgrades Leap Therapeutics to Neutral From Buy -January 29, 2025 at 07:17 am EST - Marketscreener.com
Leap halts gastric cancer program, changes course - The Pharma Letter
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipeline - MSN
Leap Therapeutics Stock Plunges To Record Low After Ending Gastric Cancer Drug Trials, Retail Bets On CRC Pipe - Asianet Newsable
Leap Therapeutics stock hits 52-week low at $0.8 By Investing.com - Investing.com Nigeria
1.39%
0.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):